Pfizer, BioNTech COVID-19 vaccine 95% effective in final analysis, will seek EUA within days

Editor's Note

Just a week after Pfizer revealed an interim analysis showing its COVID-19 vaccine to be more than 90% effective, the company on November 18 released its final efficacy analysis showing the vaccine is 95% effective, and that it protects older people who are most at risk of dying from COVID-19.

Pfizer and German partner BioNTech say they have reached a safety milestone that will allow them to apply for a Food and Drug Administration (FDA) emergency use authorization (EUA) within days.

On November 16, Moderna announced that an interim analysis of its COVID-19 vaccine showed it to be 94.5% effective. The Moderna and Pfizer vaccines are both mRNA based and require two doses.